CD8A and melanoma: Hence, combination of SREBP inhibitor (i.e., fatostatin) with anti-PD-1 reduces tumor growth and prolong survival of melanoma-bearing mice by decreasing M2-like TAM infiltrate and by stimulating CD8+ T cell reinvigoration [96].